Dermata Therapeutics Inc Total Liabilities
Dermata Therapeutics Inc total liabilities. Based on the latest financial reports, Dermata Therapeutics Inc (DRMA) has total liabilities worth $1.83 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See DRMA defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Dermata Therapeutics Inc (2019–2025)
Total liabilities of Dermata Therapeutics Inc from 2019 to 2025. This chart illustrates how Dermata Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Dermata Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Dermata Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Autozi Internet Technology (Global) Ltd. Class A Ordinary Shares
NASDAQ:AZI
|
USA | $43.59 Million |
|
J-Star Holding Co., Ltd. Ordinary Shares
NASDAQ:YMAT
|
USA | $13.93 Million |
|
Pinnacle Minerals Ltd
AU:PIM
|
Australia | AU$243.62K |
|
Maple Peak Investments Inc
V:MAP
|
Canada | CA$44.00K |
|
Hochdorf Holding AG
SW:HOCN
|
Switzerland | CHF2.24 Million |
|
Focus Universal Inc
NASDAQ:FCUV
|
USA | $705.64K |
|
MGO Global Inc. Common Stock
NASDAQ:MGOL
|
USA | $182.24K |
|
Poddar Housing and Development Limited
NSE:PODDARHOUS
|
India | Rs6.38 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Dermata Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Dermata Therapeutics Inc asset portfolio.
Liquidity & Leverage Metrics
Dermata Therapeutics Inc Total Liabilities Ratios Explained
Dermata Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | N/A | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Dermata Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Dermata Therapeutics Inc (2019–2025)
The table below shows the annual total liabilities of Dermata Therapeutics Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.64 Million | -16.85% |
| 2024-12-31 | $1.97 Million | +21.51% |
| 2023-12-31 | $1.62 Million | +75.98% |
| 2022-12-31 | $922.63K | -39.17% |
| 2021-12-31 | $1.52 Million | -59.91% |
| 2020-12-31 | $3.78 Million | +66.23% |
| 2019-12-31 | $2.28 Million | -- |
About Dermata Therapeutics Inc
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in… Read more